FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 331:676-678 September 8, 1994 Number 10 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Maier, R. F.

To the Editor: The report by Maier et al. (April 28 issue)¹ on the effect of epoetin beta (recombinant human erythropoietin) in very-low-birth-weight infants provides important new data on the efficacy and safety of the agent in this age group. However, the results of Maier et al. raise several questions. First, what does their success rate tell us about anemia in these infants? The anemia of prematurity reaches a nadir by 6 to 10 weeks of age,² a period barely covered by data on the first 45 days of life. As presented, the data could indicate that the need for . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.